Evolus Q3 revenue up 13%, fourth straight positive EBITDA quarter

What changed

Global toxin revenue rose about 11% in the quarter and about 11% year to date, compared with the same periods in 2025. Jeuveau is the product CEO David Moatazedi calls a "durable growth engine."

The HA portfolio is the growth story. Global HA gel revenue grew nearly 40% year over year in the quarter. Through the first nine months, Evolus says total revenue grew 14% and Adjusted EBITDA improved by roughly $23 million compared with 2025.

The company is also pointing at its pipeline. It has a partnership with IBSA to develop and commercialize Profhilo in the United States. Profhilo is described in the release as the market-leading skin quality injectable in Europe, and Evolus holds an exclusive license for U.S. development and commercialization. Moatazedi frames skin quality as a third category alongside toxins and HA fillers.

Separately, Evolus has an option agreement that could open procedure-based injectable hair growth. Management says the option lets it review meaningful human clinical data before committing to a larger investment. The release says the deal requires a modest near-term R&D spend and does not change the financial outlook.

The company also expects FDA approval of Evolysse Sculpt by year-end. The release calls that anticipated approval "an additional opportunity," and it does not say more about the timing or the indication.

What it means for practices (our read)

Growth at a toxin company is usually a story about share. Evolus is saying it is taking share with Jeuveau, and the 11% toxin figure is the number to watch if you stock it. A brand growing at that pace in a crowded category is buying distributor and practitioner attention, and that tends to show up in promotions and account reps.

The HA number is bigger than it looks. A 40% jump in gel revenue means more practices are testing the Evolysse line, and Evolus has a fresh reason to push it into fillers. If you already carry HA gels, expect more contact from the company, not less.

The Profhilo deal matters for a different reason. It would give Evolus a skin-quality product for U.S. practices, which is a category a lot of owners already buy from other companies. The release does not give a U.S. launch date, a price, or an FDA status for Profhilo in the United States. Treat it as a pipeline item until that changes.

What owners can do now

Pull your last twelve months of toxin and filler purchasing and compare it to what you are paying per unit. A brand growing this fast is often willing to negotiate volume terms, and you should ask before the next order.

Ask your Evolus rep three specific questions: when the Evolysse Sculpt approval is expected, what its labeled indication will be once it is granted, and whether any Profhilo U.S. timeline has been set. The release answers none of them.

If you are weighing a new HA line, check the regulatory status of each product you are offered. Evolysse HA gels are described in the release as entering the U.S. market, and the company's own forward-looking statements say that depends on Symatese, which the company names as a reliance. Ask for the actual FDA pathway in writing.

What we don't know yet

The release gives no product-level revenue split. It does not break out Jeuveau or Evolysse sales separately, so the 11% toxin and 40% HA figures cannot be tied to unit volume or to U.S. versus international sales.

The hair-growth option has no named molecule, no clinical data, and no timeline in the document. Neither does the three-new-technologies plan over four years.

Evolus also says it expects to hit a 2028 Adjusted EBITDA margin target, but the release does not state that margin or the full-year 2026 figures in dollars. The company has the full outlook in its investor materials, and the reconciliation tables in the release are the place to check the quarter's numbers against GAAP net loss.

Business information, not medical or legal advice. Verify regulatory status at FDA.gov.